Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 32 studies | 61% ± 21% | |
CD16-positive, CD56-dim natural killer cell, human | 15 studies | 75% ± 13% | |
mature NK T cell | 13 studies | 59% ± 22% | |
CD8-positive, alpha-beta T cell | 10 studies | 46% ± 19% | |
gamma-delta T cell | 10 studies | 41% ± 11% | |
CD16-negative, CD56-bright natural killer cell, human | 6 studies | 33% ± 21% | |
CD8-positive, alpha-beta memory T cell | 6 studies | 36% ± 11% | |
T cell | 5 studies | 24% ± 8% | |
effector memory CD8-positive, alpha-beta T cell, terminally differentiated | 5 studies | 55% ± 11% | |
effector CD8-positive, alpha-beta T cell | 5 studies | 43% ± 17% | |
effector memory CD8-positive, alpha-beta T cell | 5 studies | 47% ± 19% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 4 studies | 28% ± 11% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 12 studies | 19% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 67% | 588.78 | 1220 / 1809 | 88% | 36.03 | 413 / 472 |
lung | 60% | 202.94 | 345 / 578 | 45% | 45.64 | 524 / 1155 |
breast | 68% | 555.23 | 312 / 459 | 36% | 4.31 | 407 / 1118 |
spleen | 92% | 449.73 | 222 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 86% | 6.81 | 69 / 80 |
lymph node | 0% | 0 | 0 / 0 | 83% | 3.95 | 24 / 29 |
adipose | 79% | 907.19 | 954 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 78% | 1857.44 | 722 / 929 | 0% | 0 | 0 / 0 |
esophagus | 38% | 112.43 | 550 / 1445 | 39% | 40.85 | 71 / 183 |
intestine | 58% | 287.46 | 559 / 966 | 15% | 0.37 | 77 / 527 |
heart | 72% | 479.54 | 616 / 861 | 0% | 0 | 0 / 0 |
brain | 2% | 9.66 | 63 / 2642 | 68% | 12.41 | 480 / 705 |
kidney | 1% | 4.11 | 1 / 89 | 68% | 4.03 | 610 / 901 |
bladder | 38% | 89.90 | 8 / 21 | 13% | 1.89 | 67 / 504 |
adrenal gland | 4% | 10.28 | 10 / 258 | 40% | 6.00 | 91 / 230 |
thymus | 6% | 11.98 | 39 / 653 | 36% | 1.43 | 219 / 605 |
stomach | 15% | 41.39 | 55 / 359 | 21% | 0.40 | 59 / 286 |
pancreas | 0% | 0 | 0 / 328 | 30% | 0.69 | 54 / 178 |
liver | 3% | 4.05 | 6 / 226 | 27% | 0.52 | 111 / 406 |
uterus | 0% | 0 | 0 / 170 | 25% | 6.75 | 114 / 459 |
tonsil | 0% | 0 | 0 / 0 | 22% | 12.81 | 10 / 45 |
prostate | 15% | 36.42 | 37 / 245 | 7% | 0.13 | 35 / 502 |
blood vessel | 17% | 63.04 | 230 / 1335 | 0% | 0 | 0 / 0 |
ovary | 3% | 6.79 | 6 / 180 | 6% | 0.14 | 27 / 430 |
muscle | 3% | 9.15 | 22 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007267 | Biological process | cell-cell signaling |
GO_0005576 | Cellular component | extracellular region |
GO_0019838 | Molecular function | growth factor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FGFBP2 |
Protein name | Fibroblast growth factor-binding protein 2 (FGF-BP2) (FGF-binding protein 2) (FGFBP-2) (37 kDa killer-specific secretory protein) (Ksp37) (HBp17-related protein) (HBp17-RP) |
Synonyms | UNQ425/PRO1065 KSP37 |
Description | |
Accessions | ENST00000259989.7 Q9BYJ0 |